Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 1.17 trillion. The enterprise value is 1.13 trillion.
Market Cap | 1.17T |
Enterprise Value | 1.13T |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
Earnings Date | Feb 4, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Mankind Pharma has 400.66 million shares outstanding. The number of shares has increased by 0.11% in one year.
Current Share Class | n/a |
Shares Outstanding | 400.66M |
Shares Change (YoY) | +0.11% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 59.45% |
Owned by Institutions (%) | 16.10% |
Float | 94.00M |
Valuation Ratios
The trailing PE ratio is 55.23 and the forward PE ratio is 51.62. Mankind Pharma's PEG ratio is 3.14.
PE Ratio | 55.23 |
Forward PE | 51.62 |
PS Ratio | 10.58 |
PB Ratio | 11.04 |
P/TBV Ratio | 13.07 |
P/FCF Ratio | 58.33 |
P/OCF Ratio | n/a |
PEG Ratio | 3.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.72, with an EV/FCF ratio of 56.32.
EV / Earnings | 53.24 |
EV / Sales | 10.22 |
EV / EBITDA | 39.72 |
EV / EBIT | 46.62 |
EV / FCF | 56.32 |
Financial Position
The company has a current ratio of 2.95, with a Debt / Equity ratio of 0.04.
Current Ratio | 2.95 |
Quick Ratio | 2.07 |
Debt / Equity | 0.04 |
Debt / EBITDA | 0.17 |
Debt / FCF | 0.24 |
Interest Coverage | 75.89 |
Financial Efficiency
Return on equity (ROE) is 22.02% and return on invested capital (ROIC) is 14.95%.
Return on Equity (ROE) | 22.02% |
Return on Assets (ROA) | 11.97% |
Return on Capital (ROIC) | 14.95% |
Revenue Per Employee | 5.64M |
Profits Per Employee | 1.08M |
Employee Count | 19,540 |
Asset Turnover | 0.88 |
Inventory Turnover | 2.09 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.55% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +50.55% |
50-Day Moving Average | 2,645.49 |
200-Day Moving Average | 2,360.93 |
Relative Strength Index (RSI) | 63.34 |
Average Volume (20 Days) | 600,730 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 110.18 billion and earned 21.15 billion in profits. Earnings per share was 52.70.
Revenue | 110.18B |
Gross Profit | 76.55B |
Operating Income | 24.02B |
Pretax Income | 26.51B |
Net Income | 21.15B |
EBITDA | 28.16B |
EBIT | 24.02B |
Earnings Per Share (EPS) | 52.70 |
Balance Sheet
The company has 47.27 billion in cash and 4.82 billion in debt, giving a net cash position of 42.45 billion or 105.94 per share.
Cash & Cash Equivalents | 47.27B |
Total Debt | 4.82B |
Net Cash | 42.45B |
Net Cash Per Share | 105.94 |
Equity (Book Value) | 107.89B |
Book Value Per Share | 263.72 |
Working Capital | 56.43B |
Cash Flow
In the last 12 months, operating cash flow was 23.23 billion and capital expenditures -3.24 billion, giving a free cash flow of 19.99 billion.
Operating Cash Flow | 23.23B |
Capital Expenditures | -3.24B |
Free Cash Flow | 19.99B |
FCF Per Share | 49.90 |
Margins
Gross margin is 69.47%, with operating and profit margins of 21.80% and 19.20%.
Gross Margin | 69.47% |
Operating Margin | 21.80% |
Pretax Margin | 24.06% |
Profit Margin | 19.20% |
EBITDA Margin | 25.56% |
EBIT Margin | 21.80% |
FCF Margin | 18.15% |
Dividends & Yields
Mankind Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.11% |
Shareholder Yield | -0.11% |
Earnings Yield | 1.81% |
FCF Yield | 1.71% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Mankind Pharma has an Altman Z-Score of 19.
Altman Z-Score | 19 |
Piotroski F-Score | n/a |